Positive outcomes associated with stem cell transplantation in pediatric/AYA patients who receive FLAG-IDA-venetoclax for high-risk AML
Irtiza Sheikh(The University of Texas MD Anderson Cancer Center), Priti Tewari(The University of Texas MD Anderson Cancer Center), Miriam B. Garcia(The University of Texas MD Anderson Cancer Center), Branko Cuglievan(The University of Texas MD Anderson Cancer Center), Jeremy Connors(The University of Texas MD Anderson Cancer Center), David McCall(The University of Texas MD Anderson Cancer Center), Aaron E. Fan(The University of Texas MD Anderson Cancer Center), Amber Gibson(The University of Texas MD Anderson Cancer Center), Olayinka Okeleji(The University of Texas MD Anderson Cancer Center), Reeja Raj(The University of Texas MD Anderson Cancer Center), César Núnêz(The University of Texas MD Anderson Cancer Center), Samanta Catueno(The University of Texas MD Anderson Cancer Center), Demetrios Petropoulos(The University of Texas MD Anderson Cancer Center), Michael Roth(National Coalition for Cancer Survivorship)
Cited by 0
Related Papers
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
|Nature Reviews Clinical Oncology|2018|237
Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement
|The Lancet Haematology|2019|83
Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|67
Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
|Cancers|2021|66
Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer
|Nature Reviews Clinical Oncology|2021|59